Hepatic Cell News Volume 7.45 | Dec 01 2023

    By
    Jamie Kang
    -
    0
    9







    2023-12-01 | HCN 7.45


    Hepatic Cell News by STEMCELL Technologies
    Vol. 7.45 – 1 December, 2023
    TOP STORY

    VEGFA mRNA-LNP Promotes Biliary Epithelial Cell-to-Hepatocyte Conversion in Acute and Chronic Liver Diseases and Reverses Steatosis and Fibrosis

    Scientists proposed vascular-endothelial-growth-factor A (VEGFA) as a therapeutic means to accelerate biliary epithelial-cell-to-hepatocyte conversion.
    [Cell Stem Cell]

    Full ArticleGraphical Abstract
    Learn more about HepatiCult Organoid Growth Medium (Mouse)
    PUBLICATIONSRanked by the impact factor of the journal

    Hepatic Stellate Cell- and Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis

    Researchers developed an hepatic stellate cell- and microbiome-specific delivery system for dihydrotanshinone I by conjugating prebiotic-like cyclodextrin with vitamin A, utilizing PEG2000 as a linker.
    [ACS Nano]

    AbstractGraphical Abstract

    Low-Dose Radiotherapy Combined With Dual PD-L1 and VEGFA Blockade Elicits Antitumor Response in Hepatocellular Carcinoma Mediated by Activated Intratumoral CD8+ Exhausted-Like T Cells

    Investigators combined dual PD-L1 and VEGFA blockade with low-dose radiotherapy, which rapidly inflamed tumors, rendering them vulnerable to immunotherapy.
    [Nature Communications]

    Full Article

    In Vivo Reprogramming Leads to Premature Death Linked to Hepatic and Intestinal Failure

    Using complementary genetic approaches, scientists demonstrated that continuous induction of the reprogramming factors in vivo leads to hepatic and intestinal dysfunction resulting in decreased body weight and contributing to premature death.
    [Nature Aging]

    Abstract

    GPNMB+Gal-3+ Hepatic Parenchymal Cells Promote Immunosuppression and Hepatocellular Carcinogenesis

    A comprehensive single-cell transcriptome sequencing was applied to profile rat models of toxin-induced liver tumorigenesis and HCC patients.
    [EMBO Journal]

    Full ArticleGraphical Abstract

    DNA Methylation-Activated Full-Length EMX1 Facilitates Metastasis Through EMX1-EGFR-ERK Axis in Hepatocellular Carcinoma

    Scientists illuminated the crucial role of gene body hypermethylation-activated EMX1-full length in promoting tumorigenesis and metastasis in HCC.
    [Cell Death & Disease]

    Full Article

    METTL9-SLC7A11 Axis Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition

    Researchers showed that methyltransferase-like proteins 9 (METTL9) expression was elevated in HCC, and its high expression was associated with poor survival outcomes. Knockdown of METTL9 observed a significant inhibition of HCC cell viability, migration, and invasion both in vitro and in vivo.
    [Cell Death Discovery]

    Full Article

    Ergothioneine Suppresses Hepatic Stellate Cell Activation via Promoting Foxa3-Dependent Potentiation of the Hint1/Smad7 Cascade and Improves CCl4-Induced Liver Fibrosis in Mice

    Scientists reported that in LX-2 hepatic stellate cells, ergothioneine upregulated the expression of Hint1 and Smad7 and suppressed their activation provoked by TGFβ1.
    [Food & Function]

    AbstractGraphical Abstract

    Identification and Validation of Candidate Clinical Signatures of Apolipoprotein L Isoforms in Hepatocellular Carcinoma

    Apolipoprotein isoforms were explored for their associations with HCC. Diagnostic, and prognostic significance and mechanisms were explored using GSE14520 cohorts from The Cancer Genome Atlas database.
    [Scientific Reports]

    Full Article
    Scale up your cell isolation with Easy 250 EasySep™ magnet
    REVIEWS

    A Role for Immune Modulation in Achieving Functional Cure for Chronic Hepatitis B Among Current Changes in the Landscape of New Treatments

    The authors discuss options for new chronic hepatitis B therapies that could address one or more of the barriers to functional cure, with particular emphasis on the potential role of immunotherapy.
    [Expert Review Of Gastroenterology & Hepatology]

    Full Article
    INDUSTRY AND POLICY NEWS

    Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

    Algernon Pharmaceuticals, Inc. announced that it had received a notice of intention to grant from the Chinese Patent Office for the patent application entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251.
    [Algernon Pharmaceuticals, Inc.]

    Press Release
    FEATURED EVENT

    PepTalk 2024

    January 16 – 19, 2024
    San Diego, California, United States & Virtual

    > See All Events

    JOB OPPORTUNITIES

    Research Assistant – Immunological approaches to Chronic Hepatitis B Functional Cure

    National University of Singapore – Singapore, Singapore

    Postdoctoral Scholar – iPSC Disease Modeling

    University of California San Francisco – San Francisco, California, United States

    Animal Technician – Experimental Therapeutics

    BC Cancer – Vancouver, British Columbia, Canada

    Senior Scientist – Hepatitis E Virus

    Animal & Plant Health Agency – Addlestone, England, United Kingdom

    PhD Studentship – Epigenetic Regulation of Cancer Metabolism

    Nottingham Trent University – Nottingham, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2